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Patients  with  hepatocellular  carcinoma  should  be  managed  with  a  multidisciplinary  approach  framed  in
a network  where  all  the  diagnostic  techniques  and  therapeutic  resources  are  available  in  order  to  provide
the optimal  level  of  care.
Given  this  assumption,  the  Coordinating  Committee  of  the  Italian  Association  for  the  Study  of  the
Liver nominated  a  panel  of experts  to  elaborate  practical  recommendations  for  the multidisciplinary
management  of  hepatocellular  carcinoma  aiming  to provide:  (1)  homogeneous  and efﬁcacious  diagnostic
and staging  work-up,  and  (2)  the  best  treatment  choice  tailored  to  patient  status  and  tumour  stage  at
diagnosis.iver transplantation
ercutaneous ablation
rans-arterial chemoembolisation
The  2010  updated  American  Association  for  the Study  of Liver  Disease  Guidelines  for  hepatocellular  car-
cinoma  were  selected  as  the  reference  document.  For  each  management  issue,  the American  Association
for the  Study  of  Liver  Disease  recommendations  were  brieﬂy  summarised  and  discussed,  according  to  both
the  scientiﬁc  evidence  published  after  their  release  and  the  clinical  expertise  of the  Italian  centres  taking
care  of  these  patients.  The  Italian  Association  for the  Study  of  the  Liver  expert  panel  recommendations
are  ﬁnally  reported.
 Gast© 2013 Editrice
. Introduction
Patients with hepatocellular carcinoma (HCC) should be man-
ged with a multidisciplinary approach framed in a network where
ll the diagnostic techniques and therapeutic resources are avail-
ble in order to provide the optimal level of care.
Given this assumption as the pre-requisite to adequately
pproach all patients with known or suspected HCC, the follow-
ng recommendations of the Italian Association for the Study of
he Liver (AISF) aim at providing: (1) homogeneous and efﬁcacious
iagnostic and staging work-up, and (2) the best treatment choice
ailored to patient status and tumour stage at diagnosis.The AISF Coordinating Committee nominated a panel of
xperts, mainly composed by the Scientiﬁc Committee of the AISF
onothematic Conference on HCC held in Taormina, Italy, in 2009,
∗ Correspondence address: Italian Association for the Study of the Liver (Associ-
zione Italiana per lo Studio del Fegato, AISF) via Alfredo Catalani 39, 00199 Rome,
taly.  Tel.: +39 06 86399303.
590-8658/$36.00 ©  2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier
ttp://dx.doi.org/10.1016/j.dld.2013.01.012roenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
with the scope to elaborate practical recommendations for the
multidisciplinary clinical approach to HCC.
The 2010 updated American Association for the Study of Liver
Disease (AASLD) HCC Management Guidelines [1] were selected
as the reference document, because they were the most recent
guidelines applied to Western populations available at the time
of drafting this document. We believe that several aspects in the
HCC management need to be revised according to both the scien-
tiﬁc evidence published after their release and the clinical expertise
of the Italian centres taking care of these patients. Thus, for each
management issue, the main AASLD recommendations are brieﬂy
summarised and discussed, outlining the reasons for their mod-
iﬁcations whenever useful, followed by the presentation of the
relevant AISF recommendations.
The level of evidence and strength of recommendation were
graded according to the March 2009 updated version of the Oxford
Centre for Evidence-Based Medicine Level (www.cebm.net) and
reported in parentheses for each statement [2]. The concordance
rate between operators in assigning the levels of evidence was
>90%.
 Ltd. All rights reserved.
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Table 1
Adult patients at risk of developing hepatocellular carcinoma in whom surveillance
is  recommended.
• Cirrhotic patients, Child-Pugh class A and B (evidence 2b, strength B)
•  Cirrhotic patients, Child-Pugh class C awaiting liver transplantation
(evidence 5, strength D)
•  Non cirrhotic patients with chronic hepatitis B or inactive hepatitis B carriers
with viraemia >2000 UI/ml (evidence 3b, strength B for Western patients;
evidence 1b, strength A for Asian patients)
• Non cirrhotic patients with chronic hepatitis C and liver ﬁbrosis ≥F3 Metavir
(o  ≥10 kpa at transient elastography [Fibroscan®]) (evidence 5, strength D
for  Western patients; evidence 3b, strength B for Asian patients)
•  Successfully treated patients with chronic hepatitis B and C (undetectable
viraemia), but belonging to any of the previous at risk categories prior to
starting antiviral treatment (evidence 5, strength D)
N.B.: surveillance is recommended for all the above patients if they do not haveReview Article / Digestive an
. Epidemiology of HCC in Italy
Epidemiology of primary liver cancer in Italy is based upon data
erived from clinical practice and may  therefore suffer from mis-
lassiﬁcation of metastatic tumours in the liver. According to the
009–2011 report of the Italian Association of Tumor Registry, cov-
ring 50% of the Northern, 25% of Central, and 18% of the Southern
talian/Italian Islands population, the most common primary liver
ancers in the period 1998–2002 were HCC (79%), cholangiocarci-
oma (6%), carcinoma (5%), adenocarcinoma (4%), and malignant
umours (2%) [3]. The diagnosis of primary liver cancer was  based
n histology in 31% of cases.
Primary liver cancer represents the 7th most common tumour
n males (4% of all cancers) and the 13th most common tumour
n females (2.3% of all cancers), with a prevalence of 53/100,000
n males and 22/100,000 in females (male-to-female ratio = 2:1).
he lifetime (up to 74 years of age) risk of diagnosis of HCC is
7‰ in men  (1/59) and 5‰ in women (1/199). Primary liver can-
er is the 5th cause of mortality in men  (3rd in subjects 50–69
ears old) and the 7th in women (4.5% of malignancy-related
ortality).
According to recent estimates based on the World Health
rganization report, the age-adjusted mortality rate for HCC in
taly in 2009 was 4/100,000 in men  and 1/100,000 in women,
ith a 34% and 41% decrease as compared to the year 2000,
espectively [4]. The incidence/mortality ratio of primary liver
ancer in both men  and women is close to 1.0 (approximately
.3), thus emphasising the short-term lethality of this tumour. In
taly, the 5-year age-standardised relative survival of patients with
rimary liver cancer is 15% with a rather homogenous distribution
ithin the country [3].
In most cases, HCC develops in patients with cirrhosis and
herefore the risk factors for HCC and chronic liver disease are
verlapping. According to the Italian Liver Cancer (ITA.LI.CA.)
atabase, the most common cause of HCC in Italy in the
eriod 2002–2008 was hepatitis C virus (HCV) infection (49%),
ollowed by alcohol abuse (21%), mixed viral hepatitis plus alco-
ol abuse (12%), and hepatitis B virus (HBV) infection (13%)
5].
. Surveillance
.1. Target population
.1.1. Summary of 2010 AASLD guidelines
Patients at risk of developing HCC should be enrolled in
urveillance programmes for early tumour diagnosis. The annual
ncidence of HCC that triggers a favourable cost/efﬁcacy surveil-
ance programme is 0.2% in chronic hepatitis B and 1.5% in cirrhosis.
hese thresholds are reached by all cirrhotic patients and by some
ategories of patients with chronic HBV and HCV infection. Among
CV patients who have obtained a sustained virological response
SVR) to antiviral treatment, cirrhotic patients should continue
urveillance, while non-cirrhotic individuals should not undergo
urveillance because they have a low risk of developing HCC.
urveillance of patients on liver transplantation (LT) waiting list
s recommended because HCC provides transplant priority, and
he identiﬁcation of tumours exceeding the accepted limits for LT
ould result in de-listing.
.1.2. AISF expert panel comments
The fundamental pre-requisite for surveillance is the absence
f contra-indication to curative and palliative treatment of HCC.
herefore, among cirrhotic patients, surveillance should be per-
ormed in Child-Pugh class A and B patients, and class C patientscontraindications to radical and effective palliative treatments.
who  are on LT waiting list, as surveillance is not associated with
increased survival in class C patients not amenable to LT [6].
Besides the categories proposed by the AASLD, the AISF panel of
experts felt that among non-cirrhotic patients with HBV and HCV
there are some sub-categories where the probability of devel-
oping HCC is high enough to make surveillance cost-effective
(Table 1).
3.2. Surveillance tests and interval
3.2.1. Summary of 2010 AASLD guidelines
Surveillance is based on repeated liver ultrasound at 6-month
intervals. Ultrasound sensitivity for HCC is 94% but decreases to
63% for early tumours, deﬁned as one nodule <5 cm or three nod-
ules each <3 cm,  without macrovascular invasion [7]. Sensitivity for
early tumours improved by only 6% with the concurrent assessment
of alpha-fetoprotein [7]. At present, there is no role for alpha-
fetoprotein or other oncomarkers in HCC surveillance. In some
subjects, the visibility on ultrasound may  be inadequate, but there
are no sufﬁciently tested strategies to overcome this technical
limit. The performance characteristics of computed tomography
(CT) scanning in the surveillance setting are unknown, and there-
fore this technique cannot be recommended as an alternative to
ultrasound in such patients.
The 6-month surveillance interval is supported by several evi-
dences: (a) the mean doubling time of tumour volume is around
6 months [8]; (b) semiannual surveillance offered a better survival
as compared with care on demand in a randomised prospective
trial [9]; (c) this interval was superior to the 12 month interval
in both a prospective and a retrospective study [10,11] and in a
meta-regression analysis [7].
3.2.2. AISF expert panel comments
Liver ultrasound is the recommended HCC surveillance test, and
the recommended surveillance interval is 6 months. The increase
in surveillance sensitivity of the combination of ultrasound and
alpha-fetoprotein (6–8%) as compared to ultrasound alone is off-
set by an increase in false positives (from 2.9% to 7.5%) and costs
(from 2000 USD to 3000 USD per tumour identiﬁed) [7,10], thus
this combination is not recommended also by the AISF panel of
experts.
The diagnostic accuracy of ultrasound is highly dependent on
both operator’s expertise and patient’s characteristics (e.g., body
mass index, ascites, intestinal gas, thoraco-abdominal malforma-
tions, coarse liver echo-pattern, patient compliance with breathing
commands). Thus, ultrasound should be performed by a trained
operator in liver ultrasound [12]. When technical issues limit its
accuracy, this should be highlighted in the report and the possible
7  Liver Disease 45 (2013) 712– 723
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Fig. 1. Diagnostic algorithm and recall policy for cirrhotic patients with a new nod-
ule detected during ultrasound surveillance. *Since magnetic resonance imaging
(MRI) or computed tomography (CT) would be performed for hepatocellular carci-14 Review Article / Digestive and
ntegration of ultrasonography with a radiological contrast-
nhanced technique (CT, magnetic resonance imaging [MRI])
hould be considered [12–14]. In those patients who are awaiting LT
nd present a coarse liver echo-pattern, which may  impair identiﬁ-
ation of small tumours, surveillance can be performed with CT or
RI  every 6 months, taking into account that the expected surveil-
ance duration is rarely longer than 1 year and it has been reported
hat these techniques are associated with a better cost/efﬁcacy ratio
12].
The 6-month surveillance strategy is preferred to the 12-month
chedule because: (1) identiﬁes smaller lesions; (2) is associated
ith increased survival (even after adjustment for the lead-time
ias) through identiﬁcation of tumours at an earlier stage, which
re more often amenable to curative treatment; (3) is the best
ost/efﬁcacy strategy independently of aetiology of liver disease
11,13,15].
Shortening the surveillance interval to 3 months does not
ead to a better outcome in terms of: (1) cumulative inci-
ence of HCC diagnosed with a size of either ≤3 cm or ≤2 cm;
2) feasibility of HCC treatment; (3) liver-related death; and
4) rate of recall procedures and surveillance-associated costs
16].
.2.3. AISF expert panel recommendations
Patients at risk of HCC development (Table 1) should be
enrolled in surveillance programmes for early tumour detec-
tion (1a-A). Candidates for liver transplantation should be
screened regardless of Child-Pugh class, in order to detect
tumours exceeding conventional criteria and modify priority
in the waiting list (5-D).
Surveillance should be based on periodic liver ultrasound
(2a-B) performed by an experienced operator (5-D). In the
presence of conditions clearly limiting the accuracy of ultra-
sound, CT scan or MRI  may  be proposed as supplementary
imaging techniques (5-D). In patients awaiting liver transplan-
tation and presenting a coarse liver echo-pattern, surveillance
should be carried out with CT or MRI  (5-D).
The measurement of alpha-fetoprotein is not indicated as a
surveillance tool as its use, alone or in combination with ultra-
sound, does not improve the cost/efﬁcacy ratio of surveillance
(2b-B).
A surveillance interval of 6 months is recommended (2a-B).
Shortening the interval to 3 months, even in patients at higher
risk of developing HCC (5-D), is not associated with any pro-
gnostic improvement and may  worsen the cost/efﬁcacy ratio
of surveillance (1b-A).
. Recall procedures
.1. Summary of 2010 AASLD guidelines
The detection of any new focal lesion during ultrasound surveil-
ance should immediately prompt a diagnostic recall strategy that
aries according to the size of the lesion. The recall strategy for
esions ≥1 cm is based on contrast-enhanced imaging techniques
ith use of vascular contrast media. The lesion should be assessed
rior to contrast injection and after contrast injection in the
rterial, portal and venous phases (dynamic contrast imaging)
t either CT or MRI. A diagnosis of HCC can be established when
he typical vascular pattern is observed, that is a contrast uptake
hyper-enhancement) in the arterial phase (“wash-in”) followed
y “wash-out” (the lesion becomes hypo-enhancing) in the portal
r venous phase. If the radiological behaviour is not typical for
CC, the lesion should be assessed by the alternative imaging
echnique (either CT or MRI) or undergone biopsy. Bioptic samplesnoma staging after detection of a nodule by ultrasonography, the most cost-effective
approach is to prescribe in ﬁrst line MRI  or CT and to resort to contrast-enhanced
ultrasonography (CEUS) in case of inconclusive diagnosis at MRI  and/or CT.
should be assessed by a pathologist expert in the evaluation of
liver lesions, and the histological evaluation should include the use
of tissue markers to increase the diagnostic yield. Lesions <1 cm
should be entered into an enhanced follow-up programme based
on ultrasound repetition at 3–6 months interval, as the probability
of achieving a deﬁnitive diagnosis at this stage is small, due to high
rate of non-diagnostic imaging and difﬁculties in obtaining appro-
priate tissue sampling. If the size of such lesions does not increase
over a 2-year period, the semiannual surveillance can be restored.
Alpha-fetoprotein should not be used as a diagnostic test due to
the possibility of elevated levels in patients with non-HCC malig-
nancies and non-malignant diseases.
4.2. AISF expert panel comments
The proposed recall strategy for nodules identiﬁed during
surveillance is similar to that of AASLD guidelines (Fig. 1). In the
AASLD algorithm contrast-enhanced ultrasound (CEUS) was not
included among the imaging techniques for the diagnosis of HCC
of a lesion detected during surveillance. This exclusion has been
related to report of few cases in which the “wash-in/wash-out”
pattern was found to occur in histologically proven intra-hepatic
cholangiocarcinoma (ICC) [17–19]. Conversely, the AISF expert
panel considers the available scientiﬁc evidence not sufﬁcient to
remove CEUS from the diagnostic tools since a CEUS pattern typical
for HCC has a positive predictive value >95% [13,18]. Furthermore,
ICC currently accounts for 1–2% of all new nodules detected in cir-
rhosis [17,18] and, among them, only half shows the typical HCC
pattern at CEUS [19,20]. The wash-in/wash-out pattern at CEUS of
a nodule in cirrhosis should be regarded speciﬁc for malignancy
and, unless highly discordant ﬁndings with MRI  or CT are observed
(namely ring arterial enhancement and/or progressive increase in
d Liver
c
c
e
a
m
d
M
(
c
[
d
p
t
t
a
r
H
s
a
a
d
i
n
f
a
d
r
o
4
•
•
•
•
•
•Review Article / Digestive an
ontrast uptake in delayed CT/MRI vascular phase), it should be
onsidered indicative of HCC, without the need for biopsy. How-
ver, due to the need of CT or MRI  for tumour staging, use of CEUS
s ﬁrst line approach, despite possible, does not appear to be the
ost cost-effective strategy [21].
MRI  has higher sensitivity than other imaging techniques for the
etection of the typical vascular pattern in HCC <2 cm [10,22,23].
RI  is also superior for the detection of hypovascular HCC
lacking arterial hyper-enhancement) when hepatocyte-speciﬁc
ontrast agents and post-vascular phase assessments are employed
24]. A pre-contrast hyperintensity in T2 acquisitions with the
iffusion-weighted technique, and an enhancement defect in the
ost-vascular (hepato-biliary) phase with hepatocyte-speciﬁc con-
rast agents support the diagnosis of malignant lesion. However,
hese features alone are not accepted as markers of HCC in the
bsence of the typical vascular pattern [25]. The minimal technical
equirements of contrast-enhanced CT and MRI  for the diagnosis of
CC are reported online in Supplementary Materials.
Considering that the main goal of surveillance is to identify very
mall HCC (<2 cm)  that carries much lower risk of satellite nodules
nd microvascular invasion as compared to larger lesions [26,27],
nd that some HCCs may  have a doubling time of approximately 30
ays [8], the AISF expert panel suggests that the most appropriate
nterval for surveying nodules <1 cm or larger nodules with a biopsy
egative for malignancy is 3 months.
Although Eastern guidelines propose that a serum level of alpha-
etoprotein >400 ng/mL is diagnostic for HCC within the frame of
 recall strategy in patients at risk [14,28], the AISF expert panel
oes not support its use, considering the possibility of false positive
esults in patients with non-malignant diseases or malignancies
ther than HCC.
.3. AISF expert panel recommendations
Any new nodule identiﬁed during ultrasound surveillance in
patients at risk for HCC should be regarded as HCC until other-
wise demonstrated, prompting recall procedures that should
be performed within a reasonable time interval in order to
allow deﬁnite diagnosis and treatment when tumour is small
(<2 cm)  (Fig. 1, 2b-A).
In patients not included in the categories at risk for HCC listed
in Table 1, the a priori probability that a focal liver lesion is
HCC is unknown, and the ﬁnal diagnosis must be based on
histology (3b-B).
When hepatic nodule(s) and the underlying liver disease are
simultaneously identiﬁed, the criteria for HCC diagnosis are
the same adopted for nodules identiﬁed during surveillance
if the patient belongs to one of the categories at risk for HCC
reported in Table 1.
Alpha-fetoprotein should not be considered a diagnostic test
for HCC (3b-B).
If available, any previous diagnostic imaging should be
reviewed by an expert radiologist at the Institution where
the patient will be managed (5-D). Otherwise, the appropriate
diagnostic technique should be repeated. CEUS performed by
operators with speciﬁc expertise in liver diseases can be used
to characterise nodules presenting in cirrhotic livers (1b-A).
The non-invasive diagnosis of HCC is based on typical fea-
tures (homogeneous hyper-enhancement of the lesion in the
arterial phase, followed by hypo-enhancement in the venous
or delayed phase) at dynamic contrast-enhanced imaging
techniques (CT, MRI, or CEUS) (2b-B). Multiphasic MRI  with
hepatocyte-speciﬁc contrast medium may  provide additional
clues to the diagnosis of HCC (1a-A) and is superior to CT for
intra-hepatic staging of the tumour (2b-A). A global “wash-
in” followed by a very rapid (<60 s) and marked “wash-out” Disease 45 (2013) 712– 723 715
at CEUS should be regarded as not completely typical for HCC
and as potential indicator of non-hepatocellular malignancy
(e.g., intrahepatic cholangiocarcinoma) (5, D).
• Histological assessment of the nodule should be performed by
pathologists expert in liver tumours (5-D).
• If biopsy is negative for malignancy, a strict monitoring at
3-month intervals is recommended. The diagnostic recall
strategy should be restarted if the lesion changes in size or
morphology (5-D).
5. Staging
5.1. Summary of 2010 AASLD guidelines
Tumour stage, residual liver function, patient performance sta-
tus (PS), and the impact of treatment on survival should be taken
into account in order to comprehensively stage a patient with HCC.
The Barcelona Clinic Liver Cancer (BCLC) staging system is the only
staging system that includes all these parameters, its main advan-
tage being the possibility to link patient stage to treatment and to
assess prognosis on the basis of the survival rates reported by the
literature for each treatment option [29].
5.2. AISF expert panel comments
There is not an universal accepted and optimal staging system
for HCC, as the accuracy of each staging system becomes subopti-
mal  when applied to populations showing a different prevalence of
HCC stages from that observed in the population where the staging
system was  developed. Although the AISF expert panel endorses its
use, the BCLC staging system carries some limitations represented
by: (1) a unique treatment option for each stage; (2) absence of indi-
cations regarding second-line or combined/sequential treatments;
(3) inclusion of a very heterogeneous population in the intermedi-
ate stage (BCLC B) in terms of liver function and tumour burden; (4)
assignment to the advanced stage (BCLC C) of all patients with a PS
1. In the ECOG scale, PS1 refers to patients restricted in physically
strenuous activity but ambulatory and able to carry out work of
a light or sedentary nature, e.g.,  light house work, ofﬁce work; the
panel of experts does not consider this condition a contraindication
for HCC treatments.
The utility of alpha-fetoprotein as prognostic marker is still
debated, and several prognostic systems do not incorporate this
variable. However, over time changes of serum alpha-fetoprotein
may  be useful to assess response to loco-regional and systemic
treatments in patients with baseline values >200–400 ng/mL, and
to evaluate the risk of drop-out from LT waiting list [30–32].
The AASLD Guidelines do not provide recommendations on
how to assess global tumoral burden and to identify extra-hepatic
metastases. The AISF expert panel suggests the use of “panoramic”
imaging techniques, such as CT or MRI, with the latter being
preferred due to its greater accuracy for hepatic nodules <2 cm of
diameter [10,22,23]. However, the advantages of greater accuracy
is maximal in patients in the early stage, where detection of
additional HCC tiny nodules may  produce a stage migration and
where the small size of nodules make diagnosis of HCC more
challenging. Conversely, in the intermediate and advanced BCLC
stages, the detection of additional intrahepatic nodules usually
does not affect the treatment strategy. Moreover, as the likelihood
of extra-hepatic spread becomes higher at the latter stages, a chest
and bone investigations are more strongly recommended. To this
end, the slightly lower accuracy of CT for intrahepatic nodules
detection in comparison to MRI  is largely outbalanced by the possi-
bility of obtaining both an abdominal and chest investigations (plus
7  Liver
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dditional bone study for the structures contained in these regions)
n the same session, at much cheaper costs and shorter times.
A bone nuclear scan is requested only upon clinical suspicion
f bone involvement not solved by the already available imaging
echniques.
Positron emission tomography (PET) scan is not useful for stag-
ng because it has a lower resolution as compared to CT and MRI,
nd some HCCs do not show increased glucose up-take [12].
Finally, the presence of esophageal varices should be always
ssessed by upper digestive endoscopy in cirrhotic patients as it
epresents an independent predictor of death [33].
.3. AISF expert panel recommendations
The BCLC is the recommended staging system for HCC (1b-A).
Patients should not be included in the advanced stage (BCLC
C) when assignment is solely due to the presence of a PS 1 (5-
D) and the relationship between symptoms and the tumour is
uncertain.
In patients with markedly elevated or progressively increas-
ing levels, alpha-fetoprotein may  provide useful prognostic
information to assess the response to loco-regional and sys-
temic treatments and the risk of drop-out from LT waiting list
(2b-B). Thus, the AISF expert panel recommends assessment of
alpha-fetoprotein levels prior to commencing any treatment
for HCC. However, it cannot be used to guide therapeutic deci-
sions based on the best scientiﬁc evidence currently available.
Intra-hepatic staging of HCC should be assessed by MRI  when-
ever the patient appears to be a potential candidate to surgical
or ablative treatments, as this radiological technique is more
accurate, though more expensive, than CT (4-C). CT can be
preferred when the availability of MRI  may  delay diagnosis
and staging or if the MRI  results may  be affected by technical
limitations (5-D).
HCC staging should include a chest CT scan when the patient
is a candidate to surgery or HCC is beyond the Milan crite-
ria (4-C). In the latter instance, abdominal + chest CT might
be considered the most convenient approach for tumour bur-
den assessment. However, in candidates to resection with HCC
<2 cm,  CT scan of the chest is not mandatory, due to the very
low probability of extra-hepatic spread, and may  be replaced
by a chest X-ray ﬁlm.
Staging of patients with cirrhosis and HCC should include the
assessment of portal hypertension-related bleeding risk (4-C).
. Treatment
The BCLC is the only staging system that proposes a therapeu-
ic algorithm for HCC. However, the AISF expert panel points out
hat BCLC treatment allocation should be considered as a “gen-
ral frame” indicating the most beneﬁcial treatment option for
ost patients included in each stage of the disease according to
vailable trials. The deﬁnitive therapeutic choice should be perso-
alised at the individual level, taking into account several clinical
ariables and regional organisational settings that may  lead to
ombined/sequential treatments (5-D). Inclusion of patients into
herapeutic trials is suggested in the case of contra-indications to
onventional treatment or treatment failures (5-D).
.1. Surgical resection
.1.1. Summary of 2010 AASLD guidelines
Patients presenting with a single HCC may  beneﬁt from hepatic
esection in the absence of cirrhosis or, in patients with cirrhosis, if
hey have normal serum bilirubin and no clinically signiﬁcant portal
ypertension (hepatic venous pressure gradient <10 mmHg). The Disease 45 (2013) 712– 723
risk of HCC recurrence after resection exceeds 70% at 5 years. Recur-
rence includes both dissemination, which typically occurs within
the ﬁrst 3 years, and de novo occurrence of cancer, which is the
most common cause of HCC recurrence, usually at sites distant from
the resected area. Predictors of recurrence are microvascular inva-
sion and the presence of satellite lesions. There are currently no
treatments capable of preventing HCC recurrence after resection.
In this setting, neo-adjuvant and adjuvant therapies are not recom-
mended.
6.1.2. AISF expert panel comments
There is solid evidence that liver resection can be successfully
carried out also in patients with portal hypertension and multiple
hepatic lesions, when properly selected [34,35].
The size of the nodule (“single large HCC”) has a lesser impact for
resection than for loco-regional therapies [36–38] and, therefore,
these tumours should be ﬁrstly considered for surgical resection.
In the presence of multinodularity, portal hypertension or
hyperbilirubinemia surgery may  be proposed in strictly selected
cases on the basis of multidisciplinary evaluation of the patient.
Variables to be assessed in order to minimise the risk of post-
operative hepatic irreversible decompensation include number and
location of the nodules, extent of the resection necessary for radical
surgery, possibility of a laparoscopic approach, Model for End-stage
Liver Disease (MELD) score, serum sodium, comorbid illnesses, and
patient general conditions [34,35,39–41].
For patients with HCC arising in a non-cirrhotic liver, who  often
present with large tumours (average size 8 cm), surgical resection is
the ﬁrst line therapy since they tolerate large surgical parenchymal
sacriﬁce [42].
Based on the observed risk of developing an irreversible liver
failure after hepatic resection, two promising selection proto-
cols, derived from large case-series, have been proposed. Japanese
authors have based the case selection on serum bilirubin level,
indocyanine green retention rate at 15 min  and expected exten-
sion of surgical resection [43], whereas an Italian protocol relies
on MELD score, serum sodium level, and expected extension of
hepatectomy [34]. However, before their implementation in clini-
cal practice, the AISF expert panel considers necessary an external
validation.
Some studies report 5-year survival rates after surgery >20–30%
in selected HCC patients with peripheral vascular invasion (portal
branches of II and III order) [36,44]. Nonetheless, the AISF Commit-
tee recommend that this advanced surgery should be considered
only in the setting of a multidisciplinary evaluation of the patient
and in controlled prospective studies aimed at identifying individ-
ually tailored therapies for advanced HCC.
Laparoscopic HCC resection in cirrhotic patients is now prac-
ticed in highly specialised centres with results comparable to those
of conventional resection, but with less morbidity and at lower
costs [45].
For neo-adjuvant and adjuvant therapy see Section 6.4.
6.1.3. AISF expert panel recommendations
• For patients with solitary HCC and preserved liver function
without evidence of portal hypertension, liver resection is
a ﬁrst choice treatment. This is particularly true for HCC
2–5 cm,  whereas for smaller HCC (<2 cm)  the clinical outcome
of surgery is comparable to radiofrequency thermal ablation
(RFTA) if this can be safely and effectively performed (see also
Section 6.3.2). As the only available radical treatment for single
HCC > 5 cm is surgical resection, the feasibility of this option
should be always assessed also in these patients, preferably in
a multidisciplinary setting. (3b-B).
• In the presence of portal hypertension, hyperbilirubine-
mia, or multinodularity, patients must be evaluated by a
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multidisciplinary team with great expertise, and the surgical
option must be accurately weighed against the risk of decom-
pensation after surgery (4-C).
Considering the current evidence, the utility of resection in
patients with peripheral portal invasion should be validated in
comparative clinical studies with the standard palliative treat-
ment which, should be carried out in centres where highly
qualiﬁed liver surgeons are available.
Liver resection is the treatment of choice in patients with HCC
arising in a non-cirrhotic liver (3b-B).
After surgical resection, diagnostic imaging should be
repeated quarterly during the ﬁrst 2 years. Thereafter, clinical
and imaging assessment could take place twice a year (5-D).
Radiological assessment 1 month after surgery is considered
optional and should be carried out in relation to the individual
oncological proﬁle (5-D).
.2. Liver transplantation
.2.1. Summary of 2010 AASLD guidelines
Transplantation is an effective treatment option for HCC patients
ho meet the Milan criteria, and currently no recommendations
an be made regarding the opportunity to expand these criteria.
 pre-transplant treatment for HCC is considered appropriate if a
aiting list period exceeding 4–6 months is expected.
Regarding living donor liver transplant (LDLT), decision-analysis
odels suggest that its cost-effectiveness becomes favourable if
he waiting list time exceeds 7 months. However, LTLD is a very
omplex procedure that should be performed only by highly skilled
urgeons, in order to ensure the lowest possible risk of morbidity
20–40% in different series) and mortality (0.3–0.5%) to the donor.
There are insufﬁcient data to recommend or discourage the use
f speciﬁc immunosuppressive therapies in order to reduce the
rowth of extra-hepatic tumour lesions not diagnosed before LT.
.2.2. AISF expert panel comments
In patients with HCC and decompensated cirrhosis, treatments
or HCC are limited/prevented by the advanced stage of the cirrhotic
isease [34,39–41]. Therefore, LT represents the therapy of choice
n these patients when the tumour burden falls within the Milan
riteria [46–48].
LT can provide excellent results even in patients with cancer
xceeding the Milan criteria, provided they meet other criteria,
uch as those proposed by the University of San Francisco [49],
he “up-to-seven” criteria (sum of largest nodule size in centime-
res plus number of nodules ≤7) [50], or considering the “total
umour volume” (maximum total tumour volume ≤115 cm3) [51].
oreover, promising results have been obtained with the “down-
taging” treatment strategy [52,53]. In patients outside the Milan
riteria, tumour size seems to be the most important progno-
tic factor for the recurrence risk, whereas the impact of nodule
umber is controversial [51,52,54]. In any case, vascular invasion
nd presence of extra-hepatic spread are absolute contraindica-
ions to LT due to the extremely high risk of death from HCC
ecurrence.
Patients with a tumour burden close to the accepted limits for
nclusion in the waiting list have a high risk of being excluded for
isease progression, even when the waiting period is ≤6 months.
herefore, they could beneﬁt from neo-adjuvant therapy. However,
here is yet not strong evidence of the usefulness of loco-regional
herapies (ablation, trans-arterial chemioembolisation [TACE]) in
educing the risk of drop out from waiting list [55]. From a progno-
tic point of view, there are pre-operative indicators of biological
ggressiveness of the tumour, such as serum alpha-fetoprotein,
he rate of uptake of the standardised 18F-ﬂuoro-deoxyglucose Disease 45 (2013) 712– 723 717
by the tumour, and poor histological differentiation at biopsy
[56,57].
The AASLD guidelines do not provide indications about
the issue of transplant list priority. Assigning a ﬁxed arbitrary
extra-points to the biochemical MELD score of HCC patients
may  cause an imbalance in the probability of receiving the graft
favouring HCC with respect to non-HCC candidates. Therefore,
while awaiting more solid evidence, list priority should take
into account not only the tumour progression risk, but also the
response to neo-adjuvant therapy and the biochemical MELD score
[58,59].
As compared to cadaveric LT, LDLT does not increase the risk
of tumour or viral disease recurrence, and has a potential advan-
tage especially in patients with MELD score >15, although it should
be offered only by centres with signiﬁcant experience in surgical
resection and split LT [60,61].
As far as immunosuppression is concerned, a retrospective study
reported a lower HCC recurrence rate in patients receiving either a
low dose of calcineurin inhibitors or mTOR inhibitors as immuno-
suppressive regimen [62]. A retrospective study based on a large
series of the “Scientiﬁc Registry of Transplant Recipients” found
improved survival with the use of sirolimus in patients transplanted
for/with HCC, and an opposed tendency in patients without cancer
[63]. The validity of mTOR inhibitors to reduce the risk of post-LT
HCC recurrence is still under investigation.
6.2.3. AISF expert panel recommendations
• LT is a well established treatment for HCC patients, and the
Milan criteria represent the benchmark for patient selection
(1a-A).
• LT listing should be considered even in patients with interme-
diate stage HCC (BCLC B) slightly beyond Milan criteria. These
patients should be (re)-evaluated at transplant centres adopt-
ing “expanded criteria” or “down-staging” protocols (4-C).
Tumour vascular invasion and metastases always are absolute
contraindications to LT (4-C). Due to the limited accuracy of
the available indicators of recurrence, patients with non con-
ventional criteria should be considered eligible for LT only in
centres with well-established interventional algorithms or in
the context of clinical trials (5-D).
• The decision to start neo-adjuvant (or “bridge”) therapy while
awaiting LT should be taken on a case-by-case basis and
in a multidisciplinary setting (5-D). Neo-adjuvant therapy
is generally desirable in the absence of contra-indications,
and particularly for patients with an expected waiting time
exceeding 6 months or with a tumour burden close to LT fea-
sibility limits (5-D).
• The use of “ﬁxed” arbitrary extra points to the biochemi-
cal MELD of HCC patients does not seem appropriate (2b-B).
While awaiting more reliable tools, each transplant centre
should standardise the priority given to HCC  patients on the
basis of the “urgency” principles, such as biochemical MELD,
tumour extension, alpha-fetoprotein values and response to
neo-adjuvant therapy (3b-B). Nonetheless, each transplant
centre should periodically evaluate the transplant probability
for listed patients with and without HCC, in order to correct
any imbalance between the different patient categories (5-D).
• LDLT offers an additional option for improving survival of HCC
patients, but it should be performed in highly qualiﬁed centres
for liver resection and split LT. (3b-B). LDLT may  be a good
procedure for testing the results of transplant with extended
criteria in controlled clinical trials as the use of a living donor
does not harm patients with HCC within the Milan criteria as
well as patients without HCC listed for cadaveric donation (5-
D).
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Immunosuppressive therapy in patients undergoing LT
with/for HCC should not differ from that adopted for non-
tumoral patients when the tumour meets the Milan criteria
and lacks aggressive biological features (high degree of
de-differentiation, micro- or macro-vascular invasion). In
patients with aggressive HCC, the use of mTOR inhibitors
(sirolimus and everolimus) should be considered, given their
anti-neoplastic properties together with the opportunity to
reduce or eliminate the use of calcineurin inhibitors and their
associated risks (3b-B).
.3. Ablation techniques
.3.1. Summary of 2010 AASLD guidelines
Percutaneous ablation of HCC is a safe and efﬁcacious treatment
or patients with small HCC, who are not suitable for surgery or
s a “bridging” therapy to LT. Percutaneous ethanol injection (PEI)
nd radiofrequency thermal ablation (RFTA) can be equally efﬁ-
acious for lesions up to 2 cm.  However, the necrotising effect of
FTA is more predictable and signiﬁcantly better than with PEI for
arger lesions. The evaluation of response to ablation techniques
ust be assessed with contrast-enhanced imaging techniques, and
here are no data to prefer the use of either CT or MRI  for this pur-
ose. Although the optimal interval to assess response is not clearly
eﬁned, it is often suggested to evaluate response at approximately
 month and thereafter every 3–4 months after the procedure.
fter 2 years of recurrence-free follow-up, this interval can be
rolonged. In cases with increased alpha-fetoprotein before abla-
ion and a serological response to treatment, an increase of this
ncomarker during follow-up may  suggest HCC recurrence. Never-
heless, alpha-fetoprotein assessment cannot replace radiological
urveillance follow-up.
.3.2. AISF expert panel comments
Three randomised studies on percutaneous ablation versus sur-
ical resection have shown no overall and recurrence-free survival
dvantage with surgery [64–66]. A fourth randomised study carried
ut in 230 patients with HCC meeting the Milan criteria showed
 superiority of surgery (with null peri-operative mortality) as
ompared to RFTA, regardless of size and number of HCCs [67]. Con-
ersely, the most recent randomised controlled study did not show
ifferences in the 3-year mortality rate between hepatic resection
nd RFTA in patients with a HCC <4 cm and up to two nodules,
lthough the recurrence rate was greater in non surgical patients
42% vs. 32%) [68]. Lastly, a comparative study between surgery
nd RFTA carried out in patients with very early and early HCC
BCLC 0 and A) showed no survival difference after adjustment
or confounding factors and the recurrence-free survival advan-
age provided by surgery was offset by RFTA repeatability [38]. A
ulti-centre, prospective study carried out in patients with sin-
le HCC ≤2 cm reported a complete tumoral necrosis (conﬁrmed
uring follow-up) of 97%, with RFTA, without treatment-related
ortality and negligible morbidity. Moreover, in the subgroup of
atients without contra-indications to surgery, the 5-year sur-
ival rate was 68% [69]. Finally, a Markov model-based analysis
as shown that “rescue” resection after incomplete HCC necrosis
ith RFTA offers a survival chance equivalent to that of patients
reated with surgery as ﬁrst-line approach. The same study also
stimated that initial RFTA followed by “rescue” surgery would
e the most appropriate approach when surgical mortality is
1% and the risk of persistence/recurrence after RFTA is <1.9%
70].The AISF expert panel believes that any patient failing percuta-
eous ablation should be reassessed by a multidisciplinary team to
hoose the alternative treatment with the highest safety/radicality
atio, considering at ﬁrst surgery unless deﬁnitively excluded Disease 45 (2013) 712– 723
from resection already before percutaneous ablation. As compared
to surgical resection, percutaneous ablation is associated with
lower morbidity and mortality, shorter length of hospitalisation,
and lower sanitary costs [65,67,68]. In patients not suitable to a
percutaneous approach, ablation can be performed using a video-
laparoscopic route, resulting a safe and efﬁcacious method [71,72].
Meta-analyses of randomised controlled trial of comparative
studies showed that RFTA is associated with lower local recurrence
rates and longer survival than PEI [73,74]. However, complications
of RFTA are more frequent and severe, and contra-indications are
more frequent.
Percutaneous microwave ablation is increasingly being used in
clinical practice for the treatment of HCC. The safety proﬁle appears
good, although speciﬁc conﬁrmation in larger series of cirrhotic
patients is still awaited [75]. In the only comparative study with
RFTA, microwave ablation showed equivalent efﬁcacy but required
more therapeutic sessions [76].
Beside CT and MRI, CEUS has been successfully used for the
assessment of response to ablation techniques [77–79].
6.3.3. AISF expert panel recommendations
• For HCC ≤2 cm,  in the setting of a multi-disciplinary evalu-
ation, RFTA can be considered the ﬁrst-line treatment when
performed in expert centres (3b-B).
• For HCC of 2.1–3 cm,  the choice between surgery and RFTA
should be made on a case-by-case after a multi-disciplinary
evaluation (5-D)
• Patients with nodules >3 cm should be treated with surgery,
when feasible (5-D).
• In case of failure of percutaneous ablation, patients should be
reassessed by a multidisciplinary team for the most appropri-
ate treatment modality, at ﬁrst considering surgery if feasible.
• When technically feasible, RFTA should be preferred to PEI due
to better efﬁcacy and predictability of treatment result (2a-B).
• In non-resectable cases where RFTA is not feasible (due
to insufﬁcient ultrasound visibility or proximity to hollow
organs or coagulopathy), video-laparoscopic RFTA, performed
in expert centres, should be considered (5-D).
• Response to ablation can be assessed with CEUS, MRI, or
CT approximately 1 month after treatment, and every 3–4
months thereafter up to 2 years of follow-up. In this setting,
CT or MRI  should be performed every 6 months. After 2 years
of follow-up without recurrence, the usual semiannual ultra-
sound surveillance programme can be re-started (5-D).
6.4. Adjuvant therapy after radical treatment (surgery and
ablation)
6.4.1. Summary of 2010 AASLD guidelines
Adjuvant or neo-adjuvant treatments are not recommended
by the AASLD guidelines. However, there is evidence that these
treatments may be able to reduce recurrence rates and improve
recurrence-free survival after surgery or ablation. These treat-
ments include acyclic retinoids, immunotherapy with autologous
activated lymphocytes, lipodol-I131-transcatheter arterial radio-
embolisation (TARE), capecitabine, antiviral therapy (especially
interferon) [80–83].
6.4.2. AISF expert panel comments
The AISF expert panel considers that adjuvant treatments were
inconsistently associated with an increase in overall survival, and
the evidence supporting their use was  provided by small studies
without external validation.
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Fig. 2. Treatment algorithm for patients with hepatocellular carcinoma (HCC)
undergoing transcatheter arterial chemoembolisation (TACE). *The therapeutic
ﬂowchart is valid for any session of TACE. **Magnetic resonance imaging (MRI) isReview Article / Digestive an
More solid data coming from the results of meta-analyses
howed a survival beneﬁt for adjuvant antiviral therapy with inter-
eron in HCV infected patients [84–88].
.4.3. AISF expert panel recommendations
Adjuvant therapy after surgery or ablation cannot be sug-
gested on a routine basis but should be tested in prospective
studies (5-D).
When possible, antiviral therapy should always be considered,
taking into account its favourable impact on the progression
of liver disease and non-HCC-related mortality (5-D).
.5. Transcatheter arterial techniques
.5.1. Summary of 2010 AASLD guidelines
Transcatheter arterial chemoembolisation (TACE) relies on the
nfusion into the arterial branches feeding the tumour of a
hemotherapeutic agent suspended in Lipiodol, followed by an
rterial occlusion with embolising agents, most often Gelfoam
articles. Epirubicine, doxorubicine and cis-platinum are the
hemotherapeutic agents most frequently used. An embolisation
ot coupled with infusion of a chemotherapeutic agent is deﬁned
ranscatheter arterial embolisation (TAE).
TACE is the ﬁrst-line treatment for patients with large, multifo-
al, unresectable tumours, in the absence of macrovascular invasion
nd extra-hepatic spread (BCLC stage B). Patients with Child-Pugh
lass B and C are not good candidates for TACE. The treatment is
cheduled “on demand” or at ﬁxed intervals, as there is no prospec-
ive comparison to support one or other strategy. TACE with Drug-
luting Beads (DEB-TACE) reduces the frequency/severity of the
ost-TACE syndrome. A complete response to TACE is uncommon
nd cannot be ascertained by using the standard RECIST criteria.
Transcatheter arterial radio-embolisation (TARE) with lipiodol-
131 or Ittrium90 has tumoricidal effect and an acceptable risk proﬁle
ut its impact on patients survival has not been ascertained, and
herefore this technique cannot be considered standard of care.
.5.2. AISF expert panel comments
Performing selective/super-selective TACE optimises treatment
esults, as conﬁrmed by a pathologic study in explanted livers,
howing complete response in 92% of tumours smaller than 3 cm
89]. In clinical practice, TACE is also used in some Child-Pugh
 patients if not decompensated, since a few of these patients
ere included in the trials selected for the TACE meta-analysis
howing a survival beneﬁt [90]. Survival of Child-Pugh A and B7
atients treated with TACE is indeed similar, but it signiﬁcantly
eclines in Child-Pugh B8-9 cases [91]. The results of TACE and
AE are not signiﬁcantly different, despite a trend towards better
esults for TACE, while a complete response to TACE and TACE-
ike procedures is observed in 44 ± 30% of cases [92]. TACE can
nduce a liver damage, albeit generally not severe, but in 5–7%
f the cases this procedure causes liver failure with a 30 days
ortality of 2.4% [92]. Moreover, the frequent (>60% of cases) post-
mbolisation syndrome may  worsen the quality of life, for weeks
92].
An European multicenter randomised study has shown that
EB-TACE is more effective than cTACE in terms of radiological
esponse only in patients with more advanced disease (Child-Pugh
, ECOG 1, bi-lobar or relapsing HCC)) [93]. A small non-randomised
tudy demonstrated a survival advantage with DEB-TACE as com-
ared to conventional TACE (cTACE) [94], whereas a randomised
rial did not conﬁrm this result in patients with limited tumour
urden [95].
The modiﬁed Response Evaluation Criteria in Solid Tumour
mRECIST) should be used to evaluate treatment response after
ACE and, in this setting, MRI  is more efﬁcient than CT, especiallypreferable in case of conventional TACE (cTACE) since Lipiodol uptake causes beam
hardening artefacts at computed tomography (CT) and may mask residual tumour
tissue. Response to any treatment is deﬁned according to the modiﬁed Response
Evaluation Criteria in Solid Tumour (mRECIST).
in patients undergoing cTACE due to “beam-hardening” technical
artefacts secondary to lipiodol retention [96,97]. CEUS is able to
detect the viable portions of the target lesion(s) after TACE [98].
Radiological assessment of the response should be carried out with
MRI  or CT one month after TACE and every 3 months thereafter
[99]. TACE retreatment should be considered useless if no objec-
tive response according to mRECIST criteria is observed after two
consecutive treatments [99] (Fig. 2).
Two non randomised studies have demonstrated that TACE and
TARE are not different in terms of both overall survival and toxicity,
while toxic effects were lower with TARE in another large series
of patients [100–102]. TARE was reported to be effective and well
tolerated in patients with tumour portal vein thrombosis, when
TACE is contra-indicated [103].
6.5.3. AISF expert panel recommendations
• TACE is indicated in BCLC stage B patients, not eligible for
surgery or ablation (1a-A). The best candidates for TACE are
asymptomatic Child-Pugh class A patients (1b-A), although
those with a Child-Pugh score of B7 or ECOG PS 1 can also
be considered (5-D). TACE is not indicated in patients with
jaundice, untreatable ascites, main or branch portal vein
thrombosis, hepatofugal portal blood ﬂow, HCC nodules larger
than 10 cm.
• TACE can be utilised in patients with early stage HCC, if surgi-
cal or ablative techniques are not applicable due to technical
conditions and/or comorbidities.
• TACE should be carried out with a selective or super-selective
(segmental or sub-segmental) technique in order to optimise
the risk/beneﬁt ratio and increase the likelihood of complete
response of the target lesion(s) (2b-B). In the case of bi-lobar
HCCs not treatable with a super-selective approach, the option
to treat a single lobe per session should be considered (5-D).
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The presence of peripheral, segmental portal invasion is not
an absolute contra-indication to TACE (5-D). In these patients,
TACE may  be associated with systemic treatment, however, in
the frame of controlled clinical studies (5-D).
Even though TACE is the most frequently used trans-arterial
treatment for HCC, yet there is not convincing evidence in
favour of TACE over TAE in terms of patients survival (1a-A).
In the absence of radiologic evidence of disease persistence
(complete response), TACE should not be repeated, due to its
risks, costs and impact on the patient’s quality of life. There-
fore, TACE should be repeated “on demand” (5-D).
The AISF expert panel considers failure of TACE the lack of
objective response of the treated lesions after two procedures
(Fig. 2). Nonetheless, considering bi-lobar distribution, num-
ber of lesions and patient tolerability, the number of sessions
to deﬁne the failure should be established case-by-case in
multi-disciplinary decisional setting, and may  greatly vary on
an individual basis (5-D).
Response to TACE should be evaluated using the mRECIST
criteria (5-D). Results of conventional TACE should be pref-
erentially evaluated using MRI  if available (4-C), while CT and
MRI  are equivalent in evaluating results of DEB-TACE (5-D).
CEUS can be used to ascertain disease persistence in patients
in which the targets are one or two lesions. The ﬁrst radiologic
assessment of TACE results should be performed at 1 month,
and thereafter repeated at 3–4 month intervals (5-D).
DEB-TACE may  be preferred to conventional TACE in Child-
Pugh B or ECOG PS 1 patients, although additional prospective
comparisons are needed before this approach can be deﬁnitely
recommended in the clinical practice (2b-B).
TARE may  be indicated in patients with large masses and/or
portal thrombosis/invasion, but it should be utilised in the
context of prospective studies aimed at ascertaining its cost-
effectiveness proﬁle (5, D).
.6. Combined locoregional treatments
.6.1. Summary of 2010 AASLD guidelines
The AASLD guidelines do not address this topic.
.6.2. AISF expert panel comments
Four small randomised studies did not show an increased sur-
ival when combined locoregional treatments were compared to
 single technique [104–107], although a signiﬁcant reduction
f tumour recurrence was observed in two of them [104,106].
owever, the meta-analysis of these trials, including 199 treated
atients, demonstrated a signiﬁcant better survival in those receiv-
ng combined locoregional treatments [108].
The AISF expert panel outlines that the combination of locore-
ional therapies offers the maximal ﬂexibility which allows an
pproach tailored to the characteristics of each nodule in each
atient. This approach seems to be particularly valuable in patients
ith multifocal disease.
.6.3. AISF expert panel recommendations
In non-surgical cases, a combined/sequential approach (TACE
plus PEI, RFTA, or microwave ablation) should be considered,
on an individual basis, for multinodular HCCs and for each
nodule >3 cm,  after a multidisciplinary assessment (2b-B).
.7. Systemic treatment.7.1. Summary of 2010 AASLD guidelines
Systemic chemotherapy with conventional agents, octreotide,
nterferon, tamoxifen, external radiation and anti-androgenic Disease 45 (2013) 712– 723
therapy have shown no survival beneﬁt for HCC patients and
should therefore be discouraged.
Sorafenib increases the life-expectancy of Child-Pugh class A
patients with advanced (BCLC C) stage HCC, and is the recom-
mended treatment for HCC patients with preserved liver function
who  are not suitable for surgical treatment, loco-regional therapies
or non-responding to TACE [109]. Patients with HCC and end-stage
liver disease not amenable to LT or with PS >2 do not beneﬁt from
any therapeutic option for HCC, and should receive only symp-
tomatic treatment.
6.7.2. AISF expert panel comments
Sorafenib is the recommended treatment for patients with
advanced stage HCC and preserved liver function. There is no role
for other palliative systemic treatments outside clinical trials. A
recent prospective, observational, multi-centre study carried out
in patients with advanced (75%) and intermediate (25%) stage HCC
and preserved liver function (88% Child-Pugh class A) has shown
that patient requiring a decrease in sorafenib dose (400 mg/day for
>70% of the therapy period) due to the occurrence of adverse events,
retained a good therapeutic efﬁcacy and received treatment for a
longer time [110]. Therefore, in patients intolerant to the sorafenib
full-dose, the tolerability to lower dosage (400 mg/day) should be
pursued before deciding to withdraw the drug.
Sorafenib is reimbursed by the Italian National Health Service
only for patients with Child-Pugh class A and until an objective
response or a stable disease are maintained or patients are judged
to be still obtaining clinical beneﬁt from treatment.
6.7.3. AISF expert panel recommendations
• Systemic chemotherapy with conventional agents, octreotide,
interferon, tamoxifen, and anti-androgenic drugs has no role
in HCC treatment (1b-A).
• Full dose sorafenib is the recommended treatment for HCC
patients with preserved liver function who  are not amenable
to surgery and loco-regional treatments or in whom TACE
failed, according to the Italian National Health Service rules
(1b-A). In patients intolerant to full dose sorafenib, the toler-
ance to a reduced dose (400 mg/day) is to be pursued before
deﬁnitively suspending the treatment (2b-B).
• HCC patients who cannot receive any effective treatment for
HCC must receive symptomatic treatment for pain manage-
ment and nutritional and psychological support (5-D).
6.8. Treatment of hepatitis virus infection in HCC patients
6.8.1. Summary of 2010 AASLD guidelines
The AASLD guidelines do not address this topic.
6.8.2. AISF expert panel comments
Morbidity and mortality of HCC patients also depend on the
development of complications of chronic liver disease such as
bleeding, ascites, hepatic encephalopahy and bacterial infections.
This risk can be reduced by treatment aimed at curbing the
progression of liver disease. The AISF expert panel feels that a com-
prehensive approach to patients with HCC should consider, when
feasible, the treatment of the cause of the underlying liver disease.
There is evidence that hepatic necro-inﬂammatory activity is a
risk factor for the development of HCC and its “de novo” appearance
after curative treatment [111]. Stopping viral replication reduces
the activity of liver disease and decrease HCC risk. In HBsAg posi-
tive patients, this risk is indeed reduced by antiviral therapy [112].
In HCV-RNA positive patients, obtaining a SVR with anti-viral ther-
apy decreases the likelihood to develop HCC, and interferon-based
antiviral therapy after curative HCC treatment may  extend overall
d Liver
a
i
r
f
D
p
f
6
•
•
C
T
C
f
S
b
b
A
t
s
t
f
s
G
g
t
4
B
C
B
A
t
RReview Article / Digestive an
nd recurrence-free survival [86]. Moreover, stopping or lower-
ng the progression of liver disease may  increase the likelihood to
eceive curative treatment for HCC recurrences.
Therefore, a favourable impact on prognosis can be expected
rom: (1) treatment with nucleos(t)ide analogues of HBsAg, HBV-
NA positive patients with HCC; (2) antiviral therapy in HCV-RNA
ositive patients with HCC and preserved liver function success-
ully treated with curative modalities (surgery or ablation).
.8.3. AISF expert panel recommendations
All HBsAg and HBV-DNA positive patients should receive
antiviral therapy with nucleos(t)ide analogues at the time of
and after HCC treatment (2b-B).
HCV-RNA positive patients with preserved liver function
(Child-Pugh class ≤8) whose HCC has been treated with
curative intent should be considered potential candidates to
antiviral therapy (2b-B).
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